LORICRIN and neoplasm: Stratification of a subcohort of AJCC stage I tumours into low‐ or high‐risk groups according to AMBRA1/Loricrin (AMLo)8 status revealed a significant increase in the proportion of TGF‐β2‐positive tumour cells in the high‐risk group (P < 0·05; Figure 1c).